# Kim N. Chi

Source: https://onco.cc/people/kim-chi/  
OnCo record `kim-chi` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led TITAN and MAGNITUDE, bringing apalutamide to hormone-sensitive disease and niraparib to HRR-mutant prostate cancer.

## Summary

Kim Chi was principal investigator of TITAN, which established apalutamide with androgen deprivation in metastatic hormone-sensitive prostate cancer, and of MAGNITUDE, which showed niraparib plus abiraterone benefits patients with HRR gene alterations. His group at the Vancouver Prostate Centre pioneered ctDNA profiling of androgen receptor alterations. He also co-led the CCTG PR.20 and PR.17 studies.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: prostate; trialist; canada
- Role: Medical Oncologist and Chief Medical Officer, BC Cancer; Professor, University of British Columbia
- Specialisms: Prostate cancer; Androgen receptor inhibitors; PARP inhibitor combinations; Circulating tumour DNA

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Chi%20KN%5BAuthor%5D%20prostate%20apalutamide%20OR%20niraparib

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/), [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [PARP](https://onco.cc/targets/parp/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Niraparib](https://onco.cc/drugs/niraparib/)
- institutions: [BC Cancer](https://onco.cc/institutions/bc-cancer/)
- trials: [MAGNITUDE](https://onco.cc/trials/magnitude/)

---
JSON: https://onco.cc/api/v1/entities/kim-chi.json